Why the study?
Do patients with CKD have increased platelet activation and an attenuated response to dual antiplatelet therapy compared to patients without renal insufficiency?
Do patients with CKD have increased platelet activation and an attenuated response to dual antiplatelet therapy compared to patients without renal insufficiency?
Chronic kidney disease is associated with increased baseline platelet activation and a blunted response to dual antiplatelet therapy, which may contribute to higher ischemic risks in this population.
May explain excess ischemic events in CKD; leaves open optimal DAPT regimens pending prospective trials.
Patients with CKD exhibit increased platelet activation, and an attenuated response to dual antiplatelet therapy compared with patients without renal insufficiency.
No takes yet. Share an insight, caveat, or question.
Gremmel et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: